Chronic disseminated candidiasis, unspecified
ICD-10 B42.9 is a billable code used to indicate a diagnosis of chronic disseminated candidiasis, unspecified.
Chronic disseminated candidiasis is a systemic fungal infection caused by Candida species, primarily affecting immunocompromised individuals. This condition is characterized by the widespread presence of Candida in the bloodstream and various organs, leading to severe morbidity. Patients may present with nonspecific symptoms such as fever, chills, and malaise, which can progress to more severe manifestations like septic shock or multi-organ failure if not promptly treated. The diagnosis is often confirmed through blood cultures, imaging studies, and clinical evaluation. Chronic disseminated candidiasis is particularly prevalent in patients with weakened immune systems, such as those undergoing chemotherapy, organ transplantation, or those with HIV/AIDS. Treatment typically involves antifungal agents, with echinocandins, azoles, and polyenes being the mainstays of therapy. The choice of antifungal depends on the severity of the infection, the patient's overall health, and potential drug interactions. Monitoring for treatment response and potential side effects is crucial in managing this condition effectively.
Detailed clinical notes on patient history, lab results, and treatment plans.
Patients with HIV/AIDS presenting with systemic fungal infections.
Ensure documentation reflects the chronic nature and any complications arising from the infection.
Comprehensive records of chemotherapy regimens and patient responses.
Cancer patients developing candidiasis during or after chemotherapy.
Document the patient's immunocompromised state and any concurrent infections.
Used when testing for Candida species in patients suspected of having disseminated candidiasis.
Document the reason for testing and any relevant clinical findings.
Infectious disease specialists should ensure comprehensive documentation of the patient's history.
The primary treatment involves systemic antifungal therapy, typically with echinocandins, azoles, or polyenes, depending on the patient's clinical status and any potential drug interactions.
